The intersection between cannabis and cancer in the United StatesBOWLES, Daniel W; O'BRYANT, Cindy L; ROSS CAMIDGE, D et al.Critical reviews in oncology/hematology. 2012, Vol 83, Num 1, pp 1-10, issn 1040-8428, 10 p.Article

New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancerDOEBELE, Robert C; OTON, Ana B; PELED, Nir et al.Lung cancer. 2010, Vol 69, Num 1, pp 1-12, issn 0169-5002, 12 p.Article

Diagnostic Assays for Identification of Anaplastic Lymphoma Kinase―Positive Non―Small Cell Lung CancerWEICKHARDT, Andrew J; AISNER, Dara L; FRANKLIN, Wilbur A et al.Cancer. 2013, Vol 119, Num 8, pp 1467-1477, issn 0008-543X, 11 p.Article

Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor TreatmentROSS CAMIDGE, D; KONO, Scott A; FLACCO, Antonella et al.Clinical cancer research (Print). 2010, Vol 16, Num 22, pp 5581-5590, issn 1078-0432, 10 p.Article

Crizotinib in ROS1-Rearranged Non―Small-Cell Lung CancerSHAW, Alice T; OU, Sai-Hong I; DOEBELE, Robert C et al.The New England journal of medicine. 2014, Vol 371, Num 21, pp 1963-1971, issn 0028-4793, 9 p.Article

First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism StudiesYAP, Timothy A; ARKENAU, Hendrik-Tobias; LEACH, Martin O et al.Clinical cancer research (Print). 2013, Vol 19, Num 4, pp 909-919, issn 1078-0432, 11 p.Article

Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid TumorsJÄNNE, Pasi A; BOSS, David S; MILLHAM, Robert et al.Clinical cancer research (Print). 2011, Vol 17, Num 5, pp 1131-1139, issn 1078-0432, 9 p.Article

Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic StudyLEONG, Stephen; COHEN, Roger B; O'BRYANT, Cindy et al.Journal of clinical oncology. 2009, Vol 27, Num 26, pp 4413-4421, issn 0732-183X, 9 p.Article

Identifying and Targeting ROS1 Gene Fusions in Non―Small Cell Lung CancerDAVIES, Kurtis D; LE, Anh T; ALLOISIO, Marco et al.Clinical cancer research (Print). 2012, Vol 18, Num 17, pp 4570-4579, issn 1078-0432, 10 p.Article

Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung CancerRUDIN, Charles M; HANN, Christine L; RANSON, Malcolm R et al.Clinical cancer research (Print). 2012, Vol 18, Num 11, pp 3163-3169, issn 1078-0432, 7 p.Article

A Randomized, Phase II, Biomarker-Selected Study Comparing Erlotinib to Erlotinib Intercalated With Chemotherapy in First-Line Therapy for Advanced Non―Small-Cell Lung CancerHIRSCH, Fred R; KABBINAVAR, Fairooz; RUSK, Jason et al.Journal of clinical oncology. 2011, Vol 29, Num 26, pp 3567-3573, issn 0732-183X, 7 p.Article

Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non―Small Cell Lung CancerDOEBELE, Robert C; PILLING, Amanda B; VARELLA-GARCIA, Marileila et al.Clinical cancer research (Print). 2012, Vol 18, Num 5, pp 1472-1482, issn 1078-0432, 11 p.Article

Rapid-Onset Hypogonadism Secondary to Crizotinib Use in Men With Metastatic Nonsmall Cell Lung CancerWEICKHARDT, Andrew J; ROTHMAN, Micol S; SALIAN-MEHTA, Smita et al.Cancer. 2012, Vol 118, Num 21, pp 5302-5309, issn 0008-543X, 8 p.Article

Safety, Pharmacokinetic, and Pharmacodynamic Phase I Dose-Escalation Trial of PF-00562271, an Inhibitor of Focal Adhesion Kinase, in Advanced Solid TumorsINFANTE, Jeffrey R; ROSS CAMIDGE, D; MARTIN SHREEVE, S et al.Journal of clinical oncology. 2012, Vol 30, Num 13, pp 1527-1533, issn 0732-183X, 7 p.Article